Cervical cancer
Conditions
Interventions
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. Pathologically confirmed any type of cervical cancer; 3. Clinically 2018 FIGO stage IB3-IVA; 4. Have never received radiotherapy, chemotherapy, target therapy and immune therapy for cervical cancer; 5. At least one measurable lesion; 6. ECOG 0-1; 7. Expected survival time >=6 months; 8. Baseline laboratory tests meet the following criteria: (1) Bone marrow function: WBC>=4.0x10^9/L, ANC>=2.0x10^9/L, PLT>=100x10^9/L, Hb>=80g/L; (2) Liver function: serum bilirubin =60 ml/min (calculated by Cockcroft-Gault formula); (3) Coagulation function: International standard ratio of prothrombin time (INR) 1.5 ULN; (4) Heart function: Electrocardiogram is generally normal. 9. Contraception during and within 6 months after treatment. Non-lactation period; 10. The patient signs the informed consent.
Exclusion criteria
Exclusion criteria: (1) Allergies to the study drug; (2) The researchers determined that chemoradiotherapy could not be tolerated; (3) Malignant tumor of other histological origin in the previous 5 years, except for adequately treated carcinoma in situ of the cervix and basal cell or squamous cell carcinoma of the skin; (4) Severe cardiovascular disease, including uncontrolled hypertension, unstable angina, history of myocardial infarction in the past 6 months, congestive heart failure,> grade II by New York heart association classification of heart disease, severe arrhythmia, and pericardial effusion; (5) Participated in any other clinical trials within 4 weeks before study enrollment; (6) Received surgery within 4 weeks before enrollment, or the surgical wound has not fully healed; (7) Haemorrhage occurs within 4 weeks before enrollment (blood transfusion or hospitalization is required); (8) Severe infection requiring intravenous antibiotics, antifungal or antiviral treatment; (9) Long-term use of anticoagulants or vitamin K antagonists such as Warfarin, heparin or their analogues is required, but does not include use of small doses of warfarin (<=1 mg/day) or aspirin (<=100 mg/ day) for preventive purposes; (10) Suffering from mental illness and poor compliance; (11) Cases that were not considered suitable for inclusion by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| dose limiting toxicity; | — |
Countries
China
Contacts
Public ContactXiaofan Li
Beijing Cancer Hospital
Outcome results
None listed